Cargando…

A retrospective study of Reyanning mixture in elderly patients infected with SARS-CoV-2 Omicron variant

Objective: Reyanning mixture has been demonstrated to be effective in treating infected patients during the outbreak pandemic of SARS-CoV-2 Omicron variant of Coronavirus disease 2019 (COVID-19) in Shanghai 2022. The aim of this study is to further investigate the role of Reyanning mixture specifica...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Changya, Wu, Xinxin, Yang, Hongqiang, Xu, Xiangru, Chen, Caiyu, Wu, Linguangjin, Zhang, Wen, Shi, Haimei, Fei, Yuerong, Sun, Yuting, Wu, Hongze, Zhou, Shuang, Fang, Bangjiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399593/
https://www.ncbi.nlm.nih.gov/pubmed/37547325
http://dx.doi.org/10.3389/fphar.2023.1185122
_version_ 1785084277269987328
author Liu, Changya
Wu, Xinxin
Yang, Hongqiang
Xu, Xiangru
Chen, Caiyu
Wu, Linguangjin
Zhang, Wen
Shi, Haimei
Fei, Yuerong
Sun, Yuting
Wu, Hongze
Zhou, Shuang
Fang, Bangjiang
author_facet Liu, Changya
Wu, Xinxin
Yang, Hongqiang
Xu, Xiangru
Chen, Caiyu
Wu, Linguangjin
Zhang, Wen
Shi, Haimei
Fei, Yuerong
Sun, Yuting
Wu, Hongze
Zhou, Shuang
Fang, Bangjiang
author_sort Liu, Changya
collection PubMed
description Objective: Reyanning mixture has been demonstrated to be effective in treating infected patients during the outbreak pandemic of SARS-CoV-2 Omicron variant of Coronavirus disease 2019 (COVID-19) in Shanghai 2022. The aim of this study is to further investigate the role of Reyanning mixture specifically in the treatment of elderly patients. Methods: This study enrolled 1,102 elderly patients who were infected with SARS-CoV-2 Omicron variant. Of these, 291 patients received Reyanning mixture in conjunction with conventional Western medicine treatment were assigned to the treatment group, while 811 patients only received conventional Western medicine treatment were assigned to the control group. Clinical parameters including hospitalization duration, viral shedding time, and Cycle Threshold (Ct) values of novel coronavirus nucleic acid tests, as well as adverse events were recorded and analyzed in both groups. Results: There was no significant difference in baseline characteristics between two groups. In comparison to the control group, the treatment group demonstrated a substantial difference in hospitalization duration (median: 8 days vs. 10 days, HR: 0.638, 95% CI: 0.558–0.731, p < 0.001). The treatment group also showed a significantly shorter viral shedding time compared to the control group (median: 7 days vs. 8 days, HR: 0.754, 95% CI: 0.659–0.863, p < 0.001). Multivariate Cox proportional-hazards model analysis indicated that the use of Reyanning mixture was closely associated with a reduction in hospitalization duration (HR: 1.562, 95% CI: 1.364–1.789, p < 0.001) and viral shedding time (HR: 1.335, 95% CI: 1.166–1.528, p < 0.001). In addition, during the treatment process, no serious adverse event occurred in either group. Conclusion: The improvement of clinical parameters in the treatment group indicate a promising therapeutic benefit of Reyanning mixture for elderly patients infected with SARS-CoV-2 Omicron variant in the present study. Further investigations are required to validate this finding by examining the underlying mechanism and function of Reyanning mixture.
format Online
Article
Text
id pubmed-10399593
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103995932023-08-04 A retrospective study of Reyanning mixture in elderly patients infected with SARS-CoV-2 Omicron variant Liu, Changya Wu, Xinxin Yang, Hongqiang Xu, Xiangru Chen, Caiyu Wu, Linguangjin Zhang, Wen Shi, Haimei Fei, Yuerong Sun, Yuting Wu, Hongze Zhou, Shuang Fang, Bangjiang Front Pharmacol Pharmacology Objective: Reyanning mixture has been demonstrated to be effective in treating infected patients during the outbreak pandemic of SARS-CoV-2 Omicron variant of Coronavirus disease 2019 (COVID-19) in Shanghai 2022. The aim of this study is to further investigate the role of Reyanning mixture specifically in the treatment of elderly patients. Methods: This study enrolled 1,102 elderly patients who were infected with SARS-CoV-2 Omicron variant. Of these, 291 patients received Reyanning mixture in conjunction with conventional Western medicine treatment were assigned to the treatment group, while 811 patients only received conventional Western medicine treatment were assigned to the control group. Clinical parameters including hospitalization duration, viral shedding time, and Cycle Threshold (Ct) values of novel coronavirus nucleic acid tests, as well as adverse events were recorded and analyzed in both groups. Results: There was no significant difference in baseline characteristics between two groups. In comparison to the control group, the treatment group demonstrated a substantial difference in hospitalization duration (median: 8 days vs. 10 days, HR: 0.638, 95% CI: 0.558–0.731, p < 0.001). The treatment group also showed a significantly shorter viral shedding time compared to the control group (median: 7 days vs. 8 days, HR: 0.754, 95% CI: 0.659–0.863, p < 0.001). Multivariate Cox proportional-hazards model analysis indicated that the use of Reyanning mixture was closely associated with a reduction in hospitalization duration (HR: 1.562, 95% CI: 1.364–1.789, p < 0.001) and viral shedding time (HR: 1.335, 95% CI: 1.166–1.528, p < 0.001). In addition, during the treatment process, no serious adverse event occurred in either group. Conclusion: The improvement of clinical parameters in the treatment group indicate a promising therapeutic benefit of Reyanning mixture for elderly patients infected with SARS-CoV-2 Omicron variant in the present study. Further investigations are required to validate this finding by examining the underlying mechanism and function of Reyanning mixture. Frontiers Media S.A. 2023-07-20 /pmc/articles/PMC10399593/ /pubmed/37547325 http://dx.doi.org/10.3389/fphar.2023.1185122 Text en Copyright © 2023 Liu, Wu, Yang, Xu, Chen, Wu, Zhang, Shi, Fei, Sun, Wu, Zhou and Fang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Liu, Changya
Wu, Xinxin
Yang, Hongqiang
Xu, Xiangru
Chen, Caiyu
Wu, Linguangjin
Zhang, Wen
Shi, Haimei
Fei, Yuerong
Sun, Yuting
Wu, Hongze
Zhou, Shuang
Fang, Bangjiang
A retrospective study of Reyanning mixture in elderly patients infected with SARS-CoV-2 Omicron variant
title A retrospective study of Reyanning mixture in elderly patients infected with SARS-CoV-2 Omicron variant
title_full A retrospective study of Reyanning mixture in elderly patients infected with SARS-CoV-2 Omicron variant
title_fullStr A retrospective study of Reyanning mixture in elderly patients infected with SARS-CoV-2 Omicron variant
title_full_unstemmed A retrospective study of Reyanning mixture in elderly patients infected with SARS-CoV-2 Omicron variant
title_short A retrospective study of Reyanning mixture in elderly patients infected with SARS-CoV-2 Omicron variant
title_sort retrospective study of reyanning mixture in elderly patients infected with sars-cov-2 omicron variant
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399593/
https://www.ncbi.nlm.nih.gov/pubmed/37547325
http://dx.doi.org/10.3389/fphar.2023.1185122
work_keys_str_mv AT liuchangya aretrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT wuxinxin aretrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT yanghongqiang aretrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT xuxiangru aretrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT chencaiyu aretrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT wulinguangjin aretrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT zhangwen aretrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT shihaimei aretrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT feiyuerong aretrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT sunyuting aretrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT wuhongze aretrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT zhoushuang aretrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT fangbangjiang aretrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT liuchangya retrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT wuxinxin retrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT yanghongqiang retrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT xuxiangru retrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT chencaiyu retrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT wulinguangjin retrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT zhangwen retrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT shihaimei retrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT feiyuerong retrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT sunyuting retrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT wuhongze retrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT zhoushuang retrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant
AT fangbangjiang retrospectivestudyofreyanningmixtureinelderlypatientsinfectedwithsarscov2omicronvariant